NFG
SEEL

Nadler Financial Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Nadler Financial Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3
Closed -$12K – 105
2019
Q3 		$12K Buy
+3
New +$18.1K ﹤0.01% 86

Other funds holding SEEL

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Nadler Financial Group's SEEL Position: Q4 2019 in Review

Nadler Financial Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2019, closing a stake of 3 shares — an estimated $12K sold.

Nadler Financial Group first reported a position in SEEL in Q3 2019 and held it in 1 quarter. The position peaked at $12K in Q3 2019. 13 funds tracked by Wall St. Rank hold SEEL as of Q4 2019.

  • Nadler Financial Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Nadler Financial Group sold 3 Seelos Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $12K.
  • Nadler Financial Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Nadler Financial Group's Seelos Therapeutics, Inc. Common Stock position peaked at $12K in Q3 2019.
  • 13 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Nadler Financial Group's 13F filing for Q4 2019, filed 8 Jan 2020.